Brain Trauma Oncology
Advances in Treatment Options for High-grade Glioma – Current Status and Future Perspectives
Ryan T Merrell,1 Eudocia C Quant2 and Patrick Y Wen2,3
1. Neuro-oncology Fellow; 2. Neuro-oncologist; 3. Professor of Neurology, and Director, Center for Neuro-oncology, Dana Farber/ Brigham and Women’s Cancer Center, and Division of Neuro-oncology, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School
Abstract
High-grade gliomas, including glioblastoma, anaplastic astrocytoma, anaplatic oligodendroglioma and anaplastic oligoastrocytoma, account for the majority of malignant primary brain tumours diagnosed in adults. The prognosis for these tumours is poor despite multimodality therapy with surgery, radiation and/or chemotherapy. This review summarises treatment options for high-grade glioma, including standard regimens, targeted agents and novel therapies.
Keywords High-grade glioma, radiation therapy, chemotherapy, targeted molecular therapies
Disclosure: Ryan T Merrell and Eudocia C Quant have no conflicts of interest to declare. Patrick Y Wen has received research support from Amgen, Novartis, AstraZeneca, Exelixis, Boehringer-Ingelheim and Schering-Plough and is a member of advisory boards for Esai, Angiochem and Genentech. Acknowledgement: The authors gratefully acknowledge the support of the Jim Kenary Brain Tumor Research Fund. Received: 26 May 2010 Accepted: 30 June 2010 Citation: European Neurological Review, 2010;5(1):49–55 Correspondence: Patrick Y Wen, Center for Neuro-oncology, Dana Farber/Brigham and Women’s Cancer Center, SW430, 44 Binney Street, Boston, MA 02115, US. E:
pwen@partners.org
High-grade glioma (HGG) is the most common type of primary brain tumour in adults and accounts for >75% of the estimated 22,070 newly diagnosed malignant primary brain tumours in the US each year.1
than half of HGGs are glioblastoma (GBM), the most aggressive subtype. The remainder include anaplastic gliomas (AGs),1,2
setting may improve quality of life and allow time for additional therapy, but the impact on overall survival is negligible.
More such as anaplastic
astrocytoma (AA), anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA), and rarer subtypes. HGG is incurable and is responsible for a disproportionate share of cancer-related morbidity and mortality.3
Radiation Therapy for High-grade Glioma Radiation therapy (RT) has the biggest impact on overall survival for HGG of all standard treatment modalities. The addition of RT to surgery for glioblastoma (GBM) increases median survival from three to four months to approximately 12 months.15,16
This article summarises the standard treatment of adult HGG with a particular focus on recent therapeutic advances.
Standard Treatment Options for High-grade Glioma
Surgery for High-grade Glioma
Maximal surgical resection is recommended in all newly diagnosed HGG patients. Although a surgical cure is impossible, benefits of resection include improvement of symptoms related to mass effect, reduction of tumour volume11
and removal of the necrotic tumour
core, which may be resistant to radiation therapy and poorly accessible to circulating chemotherapy. Mounting evidence suggests that a near gross total resection confers a modest survival benefit compared with biopsy or subtotal resection.12–14
Surgery may be considered in recurrent HGG patients with good performance status when the tumour is accessible, symptomatic and distant from eloquent areas. Surgical resection in the recurrent
© TOUCH BRIEFINGS 2010
Additional involved-field RT is rarely offered to patients with recurrent HGG, as doses >60Gy offer marginal benefit and an increased risk of radiation necrosis.22
Small non-randomised studies have demonstrated a survival benefit for HGG patients treated with SRS at recurrence.23 However, many of the data are subject to selection bias, and this approach is not routinely utilised. Fractionated stereotactic RT has also been evaluated for treatment of recurrent HGG, but its efficacy is also unproven.24
Chemotherapy for Glioblastoma
Temozolomide has replaced nitrosureas as the standard of care for treatment of newly diagnosed GBM, based on the results of a phase
49
With optimal treatment, median survival is only 12–18 months for GBM and two to five years for AG. There have been recent advances in elucidating the molecular pathogenesis of HGG, which may provide additional prognostic information and lead to more effective treatments.4–10
Many variations of standard RT have been investigated in an attempt to increase efficacy, including using doses >60Gy, altered fractionation schemes, brachytherapy, stereotactic radiosurgery (SRS) and the use of radiosensitising agents. None of these has demonstrated additional benefit over standard fractionated RT.17,18 including chemotherapy,19 angiogenic agents21 improve outcomes.
targeted molecular agents20
Newer approaches and anti-
may potentially work synergistically with RT and
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116